QT
ACRS icon

Quantamental Technologies’s Aclaris Therapeutics ACRS Stock Holding History

Quantamental Technologies’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-7,605
Closed -$8K – 425
2019
Q3 		$8K Hold
7,605
– – ﹤0.01% 1339
2019
Q2 		$17K Buy
+7,605
New +$41.5K 0.01% 1159

Other funds holding ACRS

MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Quantamental Technologies's ACRS Position: Q4 2019 in Review

Quantamental Technologies sold out of Aclaris Therapeutics (ACRS) in Q4 2019, closing a stake of 7,605 shares — an estimated $8K sold.

Quantamental Technologies first reported a position in ACRS in Q2 2019 and held it in 2 quarters. The position peaked at $17K in Q2 2019. 79 funds tracked by Wall St. Rank hold ACRS as of Q4 2019.

  • Quantamental Technologies reported no remaining Aclaris Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Quantamental Technologies sold 7,605 Aclaris Therapeutics shares in Q4 2019, an estimated $8K.
  • Quantamental Technologies first reported a position in Aclaris Therapeutics in Q2 2019 and held it in 2 quarters.
  • Quantamental Technologies's Aclaris Therapeutics position peaked at $17K in Q2 2019.
  • 79 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2019.

Based on Quantamental Technologies's 13F filing for Q4 2019, filed 14 Feb 2020.